GO:0036094 small molecule binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036094 (small molecule binding) is a molecular function defined as binding to any low molecular weight, monomeric, non-encoded molecule.
• Small molecule binding underlies drug action, metabolic regulation, and protein quality control, including the correction of misfolding and aggregation by pharmacological chaperones.
• Small molecules can bind proteins, RNA, and conjugated biologics; examples include TLR4 inhibition by TAK-242, RNA site mapping by Chem-CLIP, and antibody-small molecule conjugates.
• Binding selectivity and affinity are governed by defined pockets and residue-specific interactions, as shown for PD-L1 inhibitors, trypsin peptidomimetics, and cardiac troponin modulators.
• Small molecule binding can be engineered to induce degradation, as with a VHL molecular glue degrader for cysteine dioxygenase 1.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to test whether a candidate binding protein is causally involved in a phenotype.
Description
Small molecule binding (GO:0036094) is a molecular function that describes the interaction of a protein or other macromolecule with a low molecular weight, monomeric, non-encoded ligand. This term captures a fundamental biochemical event that is central to pharmacology, chemical biology, and structural biology, because most drugs and many endogenous metabolites act by binding to macromolecular targets. The QuickGO definition emphasizes that the bound molecule is not genetically encoded, distinguishing it from protein-protein or protein-nucleic acid interactions that involve biopolymers. Researchers study small molecule binding to understand how ligands stabilize or disrupt target conformation, how binding pockets achieve selectivity, and how these interactions can be harnessed therapeutically [1,6]. Real examples span diverse target classes: small molecule protein binding to correct folding or stabilize native states against aggregation, selective inhibition of Toll-like receptor 4 signaling by TAK-242, mapping of small molecule-RNA binding sites, and computationally designed antibody-small molecule conjugates. The breadth of these examples illustrates why GO:0036094 is a recurring annotation in functional genomics and drug discovery pipelines [1,3,4,5].
small molecule binding At A Glance
| GO ID | GO:0036094 |
|---|---|
| GO term | small molecule binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to a small molecule, any low molecular weight, monomeric, non-encoded molecule. |
| Major function | Non-covalent interaction with low molecular weight ligands such as drugs, metabolites, and cofactors. |
| Example ligands | Small molecule inhibitors, pharmacological chaperones, molecular glue degraders, and RNA-binding small molecules [1,2,4,5]. |
| Example targets | TLR4, PD-L1, cardiac troponin, trypsin, cysteine dioxygenase 1, and RNA. |
| Related applications | Drug discovery, chemical biology, structural biology, and functional genomics [1,3,4,5,6,7,8]. |
What Is GO:0036094?
In our own words, GO:0036094 (small molecule binding) is the molecular function of selectively and non-covalently interacting with a small molecule, defined as any low molecular weight, monomeric, non-encoded molecule. This includes binding to drugs, metabolites, cofactors, and other small organic or inorganic compounds, but excludes binding to genetically encoded polymers such as proteins or nucleic acids. The term is used to annotate gene products that physically associate with such ligands, as exemplified by small molecule protein binding that corrects folding or stabilizes native states, small molecule binding to RNA, and small molecule inhibitor binding to immune checkpoint proteins.
Why Is small molecule binding Important in Cell Biology?
Small molecule binding is important because it is the molecular basis for most therapeutic interventions and for many regulatory events in the cell. Understanding how small molecules bind to proteins and RNA enables the design of selective inhibitors, stabilizers, and degraders, and it informs efforts to correct protein misfolding or aggregation in disease [1,2,4,5,6,7,8]. Because binding events can be mapped and engineered, GO:0036094 is a key annotation for target validation and for interpreting the mechanism of action of chemical probes and drugs [1,3,4,5].
• Provides the mechanistic basis for pharmacological chaperones that correct folding or stabilize native states against misfolding and aggregation.
• Enables selective inhibition of signaling receptors, as shown for TAK-242 binding to TLR4 and interference with adaptor interactions.
• Supports the design of molecular glue degraders, such as a VHL-based degrader for cysteine dioxygenase 1.
• Allows mapping of small molecule-RNA interactions, expanding the druggable target space beyond proteins.
• Underpins structure-guided optimization of inhibitor binding to immune checkpoint proteins like PD-L1.
• Informs the development of peptidomimetic inhibitors with validated binding modes, as for trypsin.
• Reveals how small molecules modulate sarcomeric proteins such as cardiac troponin.
• Facilitates the creation of antibody-small molecule conjugates with synergistic target binding.
• Is essential for interpreting chemical genomics screens and for linking a ligand to its cellular target [1,3,4,5].
• Guides CRISPR-based validation of candidate binding proteins in disease models [1,2,4,6].
Molecular Mechanism of small molecule binding
Ligand recognition and binding pocket formation
In simple terms: The target protein or RNA forms a pocket that fits the small molecule like a lock and key.
Small molecule binding begins with the formation of a binding pocket that is complementary in shape, charge, and hydrophobicity to the ligand [1,6]. Structural studies of inhibitor binding to PD-L1 have resolved residue-specific interactions that determine affinity and selectivity. Similarly, structures of small molecule binding to cardiac troponin reveal details of how ligands engage sarcomeric proteins. These pockets are often dynamic, and ligand binding can stabilize a particular conformational state.
Non-covalent interactions and binding energetics
In simple terms: The small molecule sticks to the target through many weak interactions that together create a strong bond.
Binding is driven by non-covalent forces including hydrogen bonds, van der Waals contacts, electrostatic interactions, and hydrophobic effects [1,6]. Residue-specific binding free energy calculations have been used to dissect the contribution of individual residues to small molecule inhibitor binding to PD-L1. The overall affinity and selectivity depend on the precise arrangement of these interactions within the pocket [6,7].
Conformational consequences and functional modulation
In simple terms: When the small molecule binds, it can change the shape or activity of the target.
Small molecule binding can stabilize the native state of a protein, correct misfolding, or prevent aggregation. In the case of TAK-242, binding to TLR4 selectively interferes with interactions between TLR4 and its adaptor molecules, thereby inhibiting signaling. Small molecule binding to RNA can also alter RNA function, and Chem-CLIP methods have been developed to map small molecule-RNA binding sites.
Induced degradation and molecular glue mechanisms
In simple terms: Some small molecules act like glue to bring a target protein to the cell's degradation machinery.
A distinct mechanism of small molecule binding is the molecular glue degrader, in which the small molecule simultaneously binds a target protein and an E3 ubiquitin ligase such as VHL, leading to target ubiquitination and degradation. A small-molecule VHL molecular glue degrader for cysteine dioxygenase 1 has been described, demonstrating that binding can be engineered to induce selective protein degradation.
Binding to conjugated or multivalent systems
In simple terms: Small molecules can also be attached to larger molecules like antibodies to create new binding properties.
Small molecule binding is not limited to simple binary interactions; antibody-small molecule conjugates have been computationally designed to achieve target-binding synergy. Such systems expand the utility of small molecule binding in therapeutic and diagnostic contexts. Additionally, peptidomimetic inhibitors of trypsin have been validated for their binding mode, illustrating how small molecule binding principles apply to protease inhibition.
Key Genes Involved in GO:0036094 small molecule binding
The following genes and proteins are representative examples of small molecule binding targets or mediators, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TLR4 | Toll-like receptor 4; binds small molecule inhibitor TAK-242 | Study of innate immune signaling and small molecule interference with adaptor interactions |
| VHL | E3 ubiquitin ligase component; binds molecular glue degraders | Targeted protein degradation via small molecule-induced proximity |
| CDO1 | Cysteine dioxygenase 1; target of VHL molecular glue degrader | Model for small molecule-induced degradation of metabolic enzymes |
| PD-L1 | Immune checkpoint protein; binds small molecule inhibitors | Residue-specific binding free energy analysis for inhibitor design |
| TNNI3 | Cardiac troponin I; binds small molecule modulators | Structural studies of small molecule binding to sarcomeric proteins |
| TNNT2 | Cardiac troponin T; component of troponin complex | Small molecule binding to cardiac troponin affects contractility |
| PRSS1 | Trypsin; serine protease inhibited by peptidomimetics | Validation of small molecule binding modes for protease inhibitors |
| PRSS2 | Trypsin isoform; related protease target | Peptidomimetic inhibitor design and binding mode analysis |
| HSP90 | Chaperone; binds small molecule inhibitors | Small molecule protein binding to correct folding or stabilize native states |
| HSP70 | Chaperone; binds small molecule modulators | Pharmacological chaperone strategies for misfolding diseases |
| BACE1 | Beta-secretase; binds small molecule inhibitors | Small molecule binding in neurodegeneration research |
| TTR | Transthyretin; binds small molecule stabilizers | Stabilization of native state against aggregation |
| p53 | Tumor suppressor; binds small molecule modulators | Small molecule binding to restore or modulate p53 function |
| KRAS | GTPase; binds small molecule inhibitors | Targeting small molecule binding pockets in cancer |
| RNA | Non-coding and coding RNA; binds small molecules | Mapping small molecule-RNA binding sites via Chem-CLIP |
| IgG | Antibody scaffold; conjugated with small molecules | Antibody-small molecule conjugates with designed synergy |
How Is small molecule binding Regulated?
Small molecule binding can be regulated by the availability of the ligand, the conformational state of the target, and the presence of competing interactors [1,4,6]. For example, binding of TAK-242 to TLR4 is selective and interferes with adaptor interactions, indicating that the cellular context and adaptor availability influence the functional outcome. In molecular glue systems, the formation of a ternary complex between the target, the small molecule, and an E3 ligase is required for degradation, so the expression levels of the ligase and target regulate the response. Additionally, post-translational modifications and disease-associated mutations can alter binding pockets and thus modulate small molecule binding [1,6].
small molecule binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TTR | Transthyretin amyloidosis; protein aggregation | Knock-in of disease-associated TTR mutations; small molecule stabilizer testing |
| TLR4 | Inflammatory and autoimmune signaling | TLR4 knockout and point-mutation models to test TAK-242 binding |
| PD-L1 | Cancer immune evasion | PD-L1 knockout and overexpression models for inhibitor binding studies |
| CDO1 | Metabolic regulation and cancer | CDO1 knockout and knock-in for molecular glue degrader evaluation |
| TNNI3 | Cardiomyopathy and sarcomeric dysfunction | TNNI3 point-mutation knock-in models for small molecule modulator testing |
Small molecule binding in protein misfolding and aggregation diseases
Many neurodegenerative and systemic amyloidoses involve protein misfolding and aggregation, and small molecule binding can correct folding or stabilize the native state to prevent aggregation. Pharmacological chaperones that bind to transthyretin or other amyloidogenic proteins are examples of this therapeutic strategy. Research into small molecule binding to chaperones such as HSP90 and HSP70 is also relevant for these diseases.
Small molecule binding in cancer and immune checkpoint regulation
Small molecule inhibitors that bind to immune checkpoint proteins such as PD-L1 are being developed to modulate anti-tumor immunity. Residue-specific binding free energy calculations help optimize these inhibitors for improved affinity and selectivity. In addition, small molecule binding to oncogenic targets like KRAS and p53 is an active area of cancer research.
Small molecule binding in inflammation and innate immunity
TAK-242 (resatorvid) is a small molecule inhibitor that binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules, thereby dampening inflammatory signaling. This exemplifies how small molecule binding can be used to modulate innate immune pathways in inflammatory diseases.
Small molecule binding in targeted protein degradation
Molecular glue degraders represent a new modality in which small molecule binding induces proximity between a target protein and an E3 ligase, leading to degradation. A VHL molecular glue degrader for cysteine dioxygenase 1 has been developed, highlighting the potential of this approach for diseases driven by specific proteins.
From small molecule binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of the target alter small molecule binding and downstream signaling? | CRISPR knockout cell line |
| Does a specific point mutation in the binding pocket abolish ligand binding? | Point-mutation knock-in via CRISPR |
| Can a disease-associated mutation be corrected by a small molecule? | Knock-in of the mutation and treatment with pharmacological chaperone |
| Where does the target protein localize and interact with the small molecule? | Tagged knock-in with fluorescent or affinity tag |
| Does overexpression of the target sensitize cells to the small molecule? | Overexpression cell model |
| Can a molecular glue degrader selectively degrade the target? | Knockout of E3 ligase or target, plus degrader treatment |
How to Study the small molecule binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Chem-CLIP with nanopore sequencing | Small molecule-RNA binding sites transcriptome-wide | Mapping RNA targets of small molecules |
| X-ray crystallography / cryo-EM | Three-dimensional structure of ligand-target complex | Visualizing binding pockets and interactions |
| Binding free energy calculation | Residue-specific contributions to binding affinity | Optimizing inhibitor binding to PD-L1 |
| Surface plasmon resonance (SPR) | Kinetics and affinity of small molecule binding | Characterizing TLR4-TAK-242 binding |
| Enzymatic inhibition assay | Functional inhibition of target enzyme | Validating trypsin peptidomimetic inhibitors |
| Cellular thermal shift assay (CETSA) | Target engagement in cells | Confirming small molecule binding in live cells |
| Computational docking and design | Predicted binding poses and conjugate synergy | Designing antibody-small molecule conjugates |
| Degradation assays (western blot, flow cytometry) | Target protein degradation induced by molecular glue | Evaluating VHL degrader for CDO1 |
Chem-CLIP and RNA binding site mapping
Chem-CLIP synergized with capillary electrophoresis and nanopore sequencing has been used to map small molecule-RNA binding sites, enabling transcriptome-wide identification of RNA targets. This method is valuable for studying small molecule binding to RNA, a less explored area compared to protein targets.
Structural biology and binding free energy calculations
Structures of small molecule binding to cardiac troponin have revealed details of ligand engagement. Residue-specific binding free energy calculations have provided insights into small molecule inhibitor binding to PD-L1, helping to rationalize affinity and selectivity. These approaches are essential for structure-guided design [6,8].
Biochemical and cellular binding assays
Selective binding of TAK-242 to TLR4 was demonstrated using biochemical assays that also showed interference with TLR4-adaptor interactions. Peptidomimetic trypsin inhibitors were validated for their binding mode using enzymatic and structural methods. Such assays are foundational for confirming small molecule binding in vitro and in cells [4,7].
Computational design of conjugates and degraders
Antibody-small molecule conjugates have been computationally designed to achieve target-binding synergy, illustrating the use of computational methods to engineer small molecule binding properties. Molecular glue degraders, such as the VHL-based degrader for cysteine dioxygenase 1, are also designed using structural and computational insights.
How CRISPR Can Be Used to Study GO:0036094 small molecule binding
Knockout
CRISPR knockout of a candidate small molecule binding protein can determine whether the protein is required for the cellular response to the ligand. For example, TLR4 knockout cells can be used to confirm that TAK-242 acts through TLR4. Knockout of E3 ligase components can validate molecular glue degrader mechanisms.
Point Mutation
Point mutations in the binding pocket can be introduced to test the contribution of specific residues to small molecule binding. Residue-specific binding free energy calculations can guide the selection of mutations for experimental validation. Such models are useful for dissecting binding determinants.
Knock-in
Knock-in of disease-associated mutations or tags allows study of small molecule binding in a physiologically relevant context [1,5]. For example, knock-in of a mutation that causes misfolding can be used to test pharmacological chaperones. Tagged knock-in enables visualization and mapping of small molecule binding sites.
Overexpression
Overexpression of a small molecule binding protein can sensitize cells to ligand treatment and facilitate biochemical purification of the complex. Overexpression models are also useful for screening small molecule libraries for binding and functional effects.
How EDITGENE Supports small molecule binding Research
Researchers studying small molecule binding-related genes often need to determine whether a candidate gene is causally involved in ligand response, disease progression, or drug sensitivity. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for small molecule binding research.
Frequently Asked Questions About small molecule binding
What is GO:0036094 small molecule binding?
GO:0036094 is a Gene Ontology molecular function term defined as binding to a small molecule, any low molecular weight, monomeric, non-encoded molecule.
What genes are involved in small molecule binding?
Genes encoding proteins such as TLR4, VHL, CDO1, PD-L1, and cardiac troponin subunits are examples of small molecule binding targets [2,4,6,8].
How do small molecules bind to proteins?
Small molecules bind through non-covalent interactions within a binding pocket, including hydrogen bonds, hydrophobic contacts, and electrostatic interactions [1,6].
What is the difference between small molecule binding and protein binding?
Small molecule binding involves low molecular weight, non-encoded ligands, whereas protein binding involves genetically encoded polypeptide partners.
Can small molecules bind RNA?
Yes, small molecule-RNA binding sites can be mapped using Chem-CLIP combined with capillary electrophoresis and nanopore sequencing.
What is a molecular glue degrader?
A molecular glue degrader is a small molecule that binds both a target protein and an E3 ligase, inducing target degradation, as shown for a VHL-based degrader of cysteine dioxygenase 1.
How is small molecule binding studied experimentally?
Methods include structural biology, binding free energy calculations, biochemical assays, and cellular target engagement assays [4,6,7,8].
What diseases are associated with small molecule binding?
Small molecule binding is relevant to protein misfolding diseases, cancer, inflammation, and metabolic disorders [1,2,4,6].
How can CRISPR help study small molecule binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional validation of binding proteins and their role in drug response [1,2,4,6].
What services does EDITGENE offer for small molecule binding research?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services [1,3,6].
Conclusion
GO:0036094 small molecule binding is a fundamental molecular function that underpins drug action, metabolic regulation, and protein quality control. The diversity of targets and mechanisms, from TLR4 inhibition by TAK-242 to RNA binding and molecular glue degraders, highlights the broad relevance of this term in biomedical research. CRISPR-based models are indispensable for validating the causal roles of small molecule binding proteins in health and disease, and EDITGENE offers the tools to generate such models efficiently.
References
- 1. Chiti F et al.. 2022. Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation.. Curr Opin Struct Biol 72:267-278 PMID: 34999558
- 2. Tutter A et al.. 2025. A small-molecule VHL molecular glue degrader for cysteine dioxygenase 1.. Nat Chem Biol 21(11):1688-1696 PMID: 40555806
- 3. Wang J et al.. 2025. CDRxAbs: antibody small-molecule conjugates with computationally designed target-binding synergy.. Protein Eng Des Sel 38 PMID: 40114302
- 4. Matsunaga N et al.. 2011. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules.. Mol Pharmacol 79(1):34-41 PMID: 20881006
- 5. Yang X et al.. 2025. Mapping small molecule-RNA binding sites via Chem-CLIP synergized with capillary electrophoresis and nanopore sequencing.. Nucleic Acids Res 53(6) PMID: 40156856
- 6. Xia W et al.. 2022. Insights into small molecule inhibitor bindings to PD-L1 with residue-specific binding free energy calculation.. J Biomol Struct Dyn 40(22):12277-12285 PMID: 34486939
- 7. Lyu RL et al.. 2022. Small molecule peptidomimetic trypsin inhibitors: validation of an EKO binding mode, but with a twist.. Org Biomol Chem 20(10):2075-2080 PMID: 35225309
- 8. Cai F et al.. 2016. Structures reveal details of small molecule binding to cardiac troponin.. J Mol Cell Cardiol 101:134-144 PMID: 27825981
